NEULANDLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.6
| Stock Code | NEULANDLAB | Market Cap | 19,249 Cr. | Current Price | 15,003 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 108 | Book Value | 1,257 ₹ | Dividend Yield | 0.08 % | ROCE | 18.7 % |
| ROE | 14.8 % | Face Value | 10.0 ₹ | DMA 50 | 13,879 ₹ | DMA 200 | 13,975 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 40.4 Cr. | PAT Prev Qtr | 96.5 Cr. |
| RSI | 61.0 | MACD | 472 | Volume | 28,184 | Avg Vol 1Wk | 24,983 |
| Low price | 10,578 ₹ | High price | 19,748 ₹ | PEG Ratio | 2.28 | Debt to equity | 0.16 |
| 52w Index | 48.2 % | Qtr Profit Var | -29.2 % | EPS | 139 ₹ | Industry PE | 30.1 |
📈 Chart & Trend: NEULANDLAB is trading above both its 50 DMA (13,879 ₹) and 200 DMA (13,975 ₹), confirming short-term bullish strength. RSI at 61.0 indicates mildly overbought conditions, while MACD at 472 shows strong bullish crossover. Bollinger Bands are moderately expanded, suggesting active volatility with potential breakout. The stock is trending upward but faces valuation and earnings pressure.
🔎 Momentum Signals: Entry zone is favorable near 14,600–14,750 ₹ support. Resistance lies at 15,600–15,800 ₹. A breakout above 15,800 ₹ could extend toward 16,200–16,500 ₹, while a breakdown below 14,600 ₹ risks pullback toward 14,200–14,300 ₹.
📊 Volume Trends: Current volume (28.1k) is slightly above the 1-week average (24.9k), showing moderate participation. Sustained higher volumes are needed to confirm breakout continuation.
Positive
- Trading above both 50 DMA and 200 DMA confirms bullish strength.
- EPS of 139 ₹ provides valuation support.
- ROCE (18.7%) and ROE (14.8%) highlight moderate efficiency.
- DII holdings increased (+1.12%), showing domestic institutional confidence.
Limitation
- High P/E (108) compared to industry PE (30.1) indicates steep overvaluation.
- Dividend yield remains negligible at 0.08%.
- PEG ratio of 2.28 suggests stretched growth valuation.
- Quarterly PAT declined sharply from 96.5 Cr. to 40.4 Cr.
Company Negative News
- Quarterly profit variation at −29.2% highlights earnings weakness.
- FII holdings reduced by −0.44%, reflecting cautious foreign sentiment.
Company Positive News
- DII holdings increased (+1.12%), showing domestic support.
- Price trading near mid-range of 52-week high/low, offering potential upside.
Industry
- Industry PE at 30.1 highlights NEULANDLAB trades at a steep premium.
- Pharma sector outlook remains stable, supported by long-term demand drivers.
Conclusion
⚖️ NEULANDLAB is consolidating with mild bullish signals supported by price above averages and domestic inflows. Entry near 14,600–14,750 ₹ offers favorable risk-reward, while resistance lies at 15,600–15,800 ₹. High valuation, weak earnings, and cautious foreign sentiment are key risks. A breakout above 15,800 ₹ with strong volumes could trigger momentum toward 16,200–16,500 ₹, but caution is advised.